To summarize, our study found that patients with DTC/+T2DM received a higher cumulative dose of 131I, had higher circulating levels of NT-proBNP and ST2/IL-33R, lower circulating levels of cTn I, and showed differences in the absolute number of lymphocytes and platelets, compared to patients without T2DM, providing a comprehensive understanding of the differences between the two groups. This evidence concerns the gene IL1RL1 and type 2 diabetes mellitus.